Phase L/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 3, 1999, Pages 228-234

  DeMaria, Deborah ^a   Reilly, Denise ^a   Stevenson, James P ^b   O'Dwyer, Peter J ^b   Purvis, Joseph D ^c   Graham, Martin A ^c   Lockwood, Graham ^c   Drozd, Marion ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c Sanofi Pharmaceuticals Inc   (United States)

Author keywords

Cardiac toxicity; Pharmacokinetics; Phase I trial; QT interval; Thioxanthones

Indexed keywords

ANTINEOPLASTIC AGENT; N [[1 [[2 (DIETHYLAMINO)ETHYL]AMINO] 9 OXO 9H THIOXANTHEN 4 YL]METHYL]METHANESULFONAMIDE; SR 233377; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG; SULFONAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; SOLID TUMOR; TREATMENT OUTCOME; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SULFONAMIDES; THIOXANTHENES;

EID: 0032610754     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050971     Document Type: Article

References (20)

1. 1. Bailly C, Waring MJ (1993) Preferential intercalation at AT sequences in DNA by lucanthone, hycanthone, and indazole analogs. A footprinting study. Biochemistry 32: 5985
2. 2. Corbett TH, Lowichick N, Pugh S, Polin L, Panchapor C, White K, Knight J, Demchik L, Jones J, Jones L, LoRusso P, Foster B, Horwitz JP, Rake J, Mattes K, Perni R, Powles R, Hlavac A, Wentland M, Coughlin S, Valeriote F (1995) Solid tumor activity of WIN-33377 and analogs. Proc Am Assoc Cancer Res 36: 389
3. 3. Dennis EW, Kobus W (1994) A review of the clinical pharmacology of hycanthone. Egypt J Bilharziasis 1: 35
4. 4. Drozd ML, Lockwood G, Miller B, Rosi D (1995) A column-switching high-performance liquid chromatographic assay for a novel cytotoxic thioxanthone derivative (SR233377) in mouse plasma with toxicokinetic results from a mouse LD10 study. J Chromatogr B 670: 145
5. 5. Haq MM, Legha SS, Wiseman CW, Bodey GP (1980) Hepatotoxicity of hycanthone in patients with metastatic breast cancer. Cancer Treat Rep 64: 929
6. 6. Hartman PE, Hulbert PB (1975) Genetic activity spectra of some antischistosomal compounds with particular emphasis on thioxanthenones and benzothiopyranoindazoles. J Toxicol Environment Health 1: 243
7. 7. Hulbert PB, Bueding E, Hartman PE (1974) Hycanthone analogs: dissociation of mutagenic effects from antischistosomal effects. Science 186: 647
8. 8. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL (1983) Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 2: 806
9. 9. Kovach JS, Moertel CG, Schutt AJ, Eagan RT (1979) Phase I study of hycanthone. Cancer Treat Rep 63: 1965
10. 10. Legha SS, Grose WE, Bodey GP (1978) Phase I study of hycanthone. Cancer Treat Rep 62: 1173
11. 11. LoRusso PM, Foster BJ, Wozniak A, Graham MA, Purvis J, Rake J, Drozd M, Lockwood G, Valdivieso M (1996) Phase I pharmacokinetic study of the novel antitumor agent SR233377 given every 28 days. Proc Am Assoc Cancer Res 37: 167
12. 12. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207
13. 13. Pazdur R, Chabot GG, Campbell CA, Lehmann MH, Kloner RA, Baker LH (1988) Acodazole hydrochloride: phase I trial, pharmacokinetics, and evalution of cardiotoxicity in dogs. Cancer Res 48: 4423
14. 14. Rao KA, Adlakha A, Verma-Ansil B, Meloy TD, Stanton MS (1994) Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc 69: 589
15. 15. Shinar E, Hasin Y (1984) Acute electrocardiographic changes induced by amsacrine. Cancer Treat Rep 68: 1169
16. 16. SR233377 Investigator's Brochure (1995) Sanofi Pharmaceuticals, Collegeville, PA
17. 17. Tan HL, Hou CJY, Lauer MR, Sung RJ (1995) Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 122: 701
18. 18. Trump DL, Tutsch KD, Willson JK, Remick S, Simon K, Alberti D, Grem J, Koller J, Tormey DC (1987) Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart. Cancer Res 47: 3895
19. 19. Weiss RB, Grillo-Lopez AJ, Marsoni S, Posada JG Jr, Hess F, Ross BL (1986) Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 4: 918
20. 20. Wentland MP, Perni RB, Powles RG, Klingbeil KM, Robinson RG, Rake JB, Coughlin SA (1994) Thioxanthone antitumor agents: the effects of 7-methoxy and 7-hydroxy substitutions. Proc Am Assoc Cancer Res 35: 397